Literature DB >> 34127687

C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.

Natsuki Ishida1, Tomohiro Higuchi1, Takahiro Miyazu1, Satoshi Tamura1, Shinya Tani1, Mihoko Yamade1, Moriya Iwaizumi2, Yasushi Hamaya1, Satoshi Osawa3, Takahisa Furuta4, Ken Sugimoto5.   

Abstract

We evaluated the association between endoscopic scores of colonic inflammation and fecal calprotectin (FC), fecal immunochemical occult blood test (FIT), and C-reactive protein (CRP) in patients with ulcerative colitis (UC). Endoscopic scores reflecting the most severe lesion [maximum Mayo Endoscopic Subscore (M-MES) and Ulcerative Colitis Endoscopic Index of Severity (UCEIS)] and those reflecting the inflammation of the entire colon [sum of MES (S-MES) and Ulcerative Colitis Colonoscopic Index of Severity (UCCIS)] were evaluated. FC, FIT, and CRP were measured, and their association with the four endoscopic scores was evaluated. Endoscopic scores of 78 complete colonoscopies (66 UC patients) were evaluated using the three biomarkers. FC and CRP tended to correlate more strongly with S-MES and UCCIS than with M-MES and UCEIS. In the M-MES 0, 1 group, compared to CRP, FC and FIT showed stronger correlations with S-MES and UCCIS. Conversely, in the M-MES 2, 3 group, only CRP was significantly correlated with each descriptor. CRP more strongly reflects colon-wide mucosal inflammation than FC and allows reliable assessment of inflammation throughout the colon in active UC.

Entities:  

Year:  2021        PMID: 34127687     DOI: 10.1038/s41598-021-90558-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  25 in total

Review 1.  Inflammatory bowel disease.

Authors:  Daniel K Podolsky
Journal:  N Engl J Med       Date:  2002-08-08       Impact factor: 91.245

2.  Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

Authors:  Jean Frédéric Colombel; Paul Rutgeerts; Walter Reinisch; Dirk Esser; Yanxin Wang; Yinghua Lang; Colleen W Marano; Richard Strauss; Björn J Oddens; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Daniel Present; Bruce E Sands; William J Sandborn
Journal:  Gastroenterology       Date:  2011-06-30       Impact factor: 22.682

3.  Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test.

Authors:  Shiho Takashima; Jun Kato; Sakiko Hiraoka; Asuka Nakarai; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada; Takehiro Tanaka; Kazuhide Yamamoto
Journal:  Am J Gastroenterol       Date:  2015-03-31       Impact factor: 10.864

4.  Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis.

Authors:  Liaz Zilberman; Nitsan Maharshak; Yaron Arbel; Ori Rogowski; Meirav Rozenblat; Itzhak Shapira; Shlomo Berliner; Nadir Arber; Iris Dotan
Journal:  Digestion       Date:  2006-07-12       Impact factor: 3.216

5.  Correlation of C-reactive protein with clinical and endoscopic activity in patients with ulcerative colitis.

Authors:  Sami Karoui; Sonia Laz; Meriem Serghini; Norsaf Bibani; Jalel Boubaker; Azza Filali
Journal:  Dig Dis Sci       Date:  2010-12-03       Impact factor: 3.199

6.  Correlation of serum biomarkers with clinical severity and mucosal inflammation in Chinese ulcerative colitis patients.

Authors:  Ka Ho Lok; Chi Ho Ng; Hiu Gong Hung; Kam Fu Li; Kin Kong Li; Ming Leung Szeto
Journal:  J Dig Dis       Date:  2008-11       Impact factor: 2.325

7.  C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study.

Authors:  M Henriksen; J Jahnsen; I Lygren; N Stray; J Sauar; M H Vatn; B Moum
Journal:  Gut       Date:  2008-06-19       Impact factor: 23.059

8.  Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Motoaki Kuriyama; Mitsuhiro Akita; Tomoko Hirakawa; Hiroyuki Okada; Kazuhide Yamamoto
Journal:  Am J Gastroenterol       Date:  2012-09-25       Impact factor: 10.864

9.  Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis.

Authors:  Taro Osada; Toshifumi Ohkusa; Isao Okayasu; Tsutomu Yoshida; Shu Hirai; Kazuko Beppu; Tomoyoshi Shibuya; Naoto Sakamoto; Osamu Kobayashi; Akihito Nagahara; Takeshi Terai; Sumio Watanabe
Journal:  J Gastroenterol Hepatol       Date:  2008-12       Impact factor: 4.029

10.  Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis.

Authors:  Mayu Uchihara; Jun Kato; Saya Tsuda; Takeichi Yoshida; Takao Maekita; Mikitaka Iguchi; Masayuki Kitano
Journal:  JGH Open       Date:  2017-11-01
View more
  5 in total

1.  [Improved Mayo Endoscopic Score has a higher value for evaluating clinical severity of ulcerative colitis].

Authors:  Z Song; M Zhang; Y Ren; B Iang
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-07-20

Review 2.  Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology?

Authors:  Panu Wetwittayakhlang; Livia Lontai; Lorant Gonczi; Petra A Golovics; Gustavo Drügg Hahn; Talat Bessissow; Peter L Lakatos
Journal:  J Clin Med       Date:  2021-11-26       Impact factor: 4.241

3.  Methylation of RUNX3 Promoter 2 in the Whole Blood of Children with Ulcerative Colitis.

Authors:  Emilia Dybska; Jan Krzysztof Nowak; Aleksandra Banaszkiewicz; Anna Szaflarska-Popławska; Jarosław Kierkuś; Jarosław Kwiecień; Urszula Grzybowska-Chlebowczyk; Jarosław Walkowiak
Journal:  Genes (Basel)       Date:  2022-09-01       Impact factor: 4.141

4.  Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study.

Authors:  Natsuki Ishida; Masanao Kaneko; Yusuke Asai; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  BMC Gastroenterol       Date:  2022-09-15       Impact factor: 2.847

Review 5.  Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease.

Authors:  Kohei Wagatsuma; Yoshihiro Yokoyama; Hiroshi Nakase
Journal:  Life (Basel)       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.